600080.SH
ST金花
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.69
−2.09%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 563.7M | 544.0M | 585.5M | 565.4M | 579.4M |
| Cost of Revenue | 126.9M | 125.1M | 126.8M | 133.8M | 138.0M |
| Gross Profit | 436.7M | 418.9M | 458.7M | 431.7M | 441.4M |
| Operating Expenses | |||||
| R&D Expense | 23.5M | 30.8M | 29.0M | 15.1M | 15.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 49.3M | 47.0M | 53.7M | 72.5M | 63.2M |
| Selling & Marketing Expense | 345.6M | 326.2M | 353.7M | 342.4M | 346.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 424.7M | 408.8M | 443.1M | 437.1M | 433.6M |
| Cost and Expenses | 551.6M | 533.9M | 569.9M | 570.9M | 571.6M |
| Operating Income (EBIT) | 21.1M | 17.9M | 49.0M | (32.9M) | 17.1M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 21.7M | 18.6M | 42.0M | (41.1M) | 47.9M |
| Income Tax Expense | 3.7M | 3.2M | (31.6M) | 1.8M | 14.4M |
| Bottom Line | |||||
| Net Income | 18.3M | 15.6M | 74.6M | (42.9M) | 33.5M |
| Earnings from Cont. Ops | 18.0M | 15.3M | 73.2M | (25.0M) | 56.0M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 18.3M | 15.6M | 74.6M | (42.9M) | 33.5M |
| Per Share | |||||
| Basic EPS | CN¥0.05 | CN¥0.04 | CN¥0.21 | (CN¥0.11) | CN¥0.09 |
| Diluted EPS | CN¥0.05 | CN¥0.04 | CN¥0.21 | (CN¥0.11) | CN¥0.09 |
| Revenue Per Share | CN¥1.59 | CN¥1.54 | CN¥1.64 | CN¥1.51 | CN¥1.56 |
| Shares | |||||
| Basic Shares Outstanding | 355.3M | 352.4M | 357.3M | 373.3M | 371.8M |
| Diluted Shares Outstanding | 355.3M | 352.4M | 357.3M | 373.3M | 371.8M |
| Profitability Metrics | |||||
| EBITDA | — | 34.7M | 66.0M | 4.2M | 45.7M |
| D&A | — | 16.8M | 17.0M | 37.1M | 28.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026